Faster and better targeted antibiotic care with investment in Shanx

ShanX is developing a user-friendly point-of-care diagnostic system that allows for immediate determination of which antibiotic is effective against an infection. This enables ShanX to reduce the current diagnostic turnaround time from two to three days to the same day, resulting in faster and better treatment for patients.

Targeted antibiotics

Faster diagnostics are crucial in the fight against antimicrobial resistance (AMR), one of the biggest global health threats. By prescribing the correct antibiotics more quickly, unnecessary or ineffective usage can be reduced. This approach alone can lead to millions of euros in healthcare savings per year in the Netherlands. 

“Fast and accessible diagnostics help general practitioners to choose the right treatment immediately and prevent unnecessary use. With this investment, we support Dutch innovation that improves patient care and helps to keep healthcare costs manageable,” says Mats Wassink, investment manager at Invest-NL. 

Preparation for market introduction

Invest-NL is investing together with lead investor Borski Fund, NextGen Ventures, the Brabantse Ontwikkelingsmaatschappij, CbusineZ and a strategic angel investor. The funding aims to accelerate further development, clinical validation, and preparation for the system’s market launch.